Clinical trial
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density…
NCT00240305 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00240305 |
|---|---|
| Title | A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome |
| Official title | A Randomised, Double-Blind, Placebo Controlled, Crossover Dose-Ranging Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome, Dyslipidemia |
| Intervention type | Drug |
| Interventions | Rosuvastatin |
| Enrollment | 15 |
| Start date | Apr 1, 2004 |
| Completion | May 1, 2006 |
| First posted | Oct 18, 2005 |
| Last update posted | Mar 16, 2009 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: